A Phase 1 Study of Anti-Human EGFR (Vectibix Sequence) Targeted EDVs Carrying the Cytotoxic Drug PNU-159682 (EGFR-VEDVsPNU) with Concurrent Non-Targeted EDVs Carrying an Immunomodulatory Adjuvant (EDVs40-mer) in Subjects with Advanced Solid Tumours who have No Curative Treatment Options
Phase of Trial: Phase I
Latest Information Update: 15 Jun 2018
At a glance
- Drugs PNU 159682 (Primary) ; Adjuvants
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Acronyms Designer EDV / ENG8
- Sponsors EnGeneIC
- 08 Mar 2018 Status changed from suspended to recruiting.
- 28 Feb 2018 Anticipated date last participant enrolled is 4 Feb 2019 as per Australian New Zealand Clinical Trials Registry
- 28 Feb 2018 Planned number of patients changed from 30 to 20.